---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-000239"
form_type: "8-K"
ticker: "CDIO"
cik: "0001870144"
company_name: "Cardio Diagnostics Holdings, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:48:57.609758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cardio Diagnostics holds investor call; highlights $854 CMS rate, new CLIA lab, and India expansion

## Summary
- Investor presentation reveals $854 final CMS gapfill rate for both Epi+Gen CHD and PrecisionCHD tests.
- New internal CLIA lab reduces initial COGS by ~30%; further reductions expected at scale.
- TAM estimated at ~$176B across both tests, with 146M and 60M eligible Americans respectively.
- Announced partnership with Aimil Ltd and Dr. Lal PathLabs for India expansion of PrecisionCHD.
- Preliminary data on PrecisionCHD presented at AHA and ACC conferences showing INOCA detection and ACS mortality prediction.

## SEC filing metadata
- accession: 0001079973-26-000239
- form_type: 8-K
- ticker: CDIO
- cik: 0001870144
- company_name: Cardio Diagnostics Holdings, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870144/000107997326000239/0001079973-26-000239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870144/000107997326000239/cdio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-000239
- JSON: https://secwatch.observer/filing/0001079973-26-000239.json
- Plain text: https://secwatch.observer/filing/0001079973-26-000239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.